Breakthrough Therapy Designation and Strong Cash Position Set Stage for Larimar’s Next Chapter in Rare Disease Innovation
Market Chameleon (Fri, 20-Mar 10:49 AM)
Larimar Therapeutics Prices $100 Million Upsized Public Offering—What This Means for Its Rare Disease Pipeline
Market Chameleon (Thu, 26-Feb 7:08 AM)
Larimar Therapeutics Secures FDA Breakthrough Therapy Designation: What’s Next for Nomlabofusp in Friedreich's Ataxia?
Market Chameleon (Wed, 25-Feb 10:28 AM)
Larimar Secures FDA Breakthrough Therapy Designation for Nomlabofusp; BLA Submission and Global Phase 3 Plans on Track
Market Chameleon (Tue, 24-Feb 9:52 AM)
FDA Grants Breakthrough Therapy Designation to Larimar’s Nomlabofusp, Targeting Friedreich’s Ataxia—BLA Submission on Track for June 2026
Market Chameleon (Tue, 24-Feb 7:54 AM)
